Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. The primary objective of the trial was to evaluate the safety and tolerability of IMO-8400 over a 12-week treatment period, with a secondary objective to evaluate the clinical activity of IMO-8400. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) shares after opening at $2.98 moved to $3.05 on last trade day and at the end of the day closed at $2.83. Company price to sales ratio in past twelve months was calculated as 4958.52 and price to cash ratio as 7.93. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) showed a negative weekly performance of -0.35%.
Insmed Incorporated (NASDAQ:INSM) announced the results of phase II clinical trials led by a researcher at The University of Texas Health Sciences Center for the company’s lead pipeline drug ARIKAYCE, the first of its kind in treating patients affected with Non-Tuberculous Mycobacteriae (NTM) lung infections. Insmed Incorporated (NASDAQ:INSM) shares fell -5.08% in last trading session and ended the day on $12.70. INSM return on equity ratio is recorded as -43.70% and its return on assets is -34.60%. Insmed Incorporated (NASDAQ:INSM) yearly performance is 32.02%.
BIND Therapeutics, Inc. (NASDAQ:BIND) will hold its annual meeting of stockholders (the “2014 Annual Meeting”) on May 28, 2014 at 8:00 a.m. Eastern time, at the offices of Latham & Watkins LLP, John Hancock Tower, 20th Floor, 200 Clarendon Street, Boston, Massachusetts 02116. BIND Therapeutics Inc. (NASDAQ:BIND) shares moved down -7.55% in last trading session and was closed at $8.70, while trading in range of $8.60 – $9.65. BIND Therapeutics Inc. (NASDAQ:BIND) year to date (YTD) performance is -42.35%.
Raleigh specialty pharmaceutical company Dara Biosciences Inc. (NASDAQ:DARA) filed notice to sell additional shares, with a proposed maximum sale of $32.5 million. DARA Biosciences Inc. (NASDAQ:DARA) weekly performance is -16.43%. On last trading day company shares ended up $1.78. DARA Biosciences Inc. (NASDAQ:DARA) distance from 50-day simple moving average (SMA50) is -35.71%. Analysts mean target price for the company is $2.00.
Leave a Reply